Elsevier

Lung Cancer

Volume 78, Issue 2, November 2012, Pages 144-147
Lung Cancer

EGFR mutations and human papillomavirus in lung cancer

https://doi.org/10.1016/j.lungcan.2012.08.011Get rights and content

Abstract

Our previous study reported a frequent detection of human papillomavirus (HPV) genome in primary lung adenocarcinomas of the recurrent patients who were responsive to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, suggesting that HPV presence in lung cancer may be related to a genetic background related to EGFR mutations. The present study examined the association between the HPV presence and mutations in exons 19 and 21 of EGFR gene in Japanese lung cancer patients. Thirteen (31%) out of 42 cases had EGFR mutations. Although these mutations were tended to be observed in females, non-smokers, or adenocarcinomas, there was no statistically significant associations. HPV DNA was found in 7/42 (17%) lung tumors. The frequency of HPV presence did not differ in histological types. The presence of HPV DNA was significantly related to EGFR mutations (P = 0.021), especially in adenocarcinomas of the lung (P = 0.014). HPV-positive lung tumors accounted for 38% and 7% of those with and without EGFR mutations, respectively. Our results suggest that EGFR mutations are associated with HPV presence in Japanese patients with lung cancer.

Introduction

Human papillomavirus (HPV) is a well-established risk factor of cervical cancer [1]. HPV types 16 and 18 are classified as carcinogenic to humans (Group 1) by International Agency for Research on Cancer [2], and these HPV types were also detected in a part of lung cancer [3]. In spite of many studies reporting the HPV presence, its role in lung carcinogenesis is still unclear. Although HPV-16 integration in host genome has been reported in the most of HPV-16-positive lung squamous cell carcinomas (SQCs) [4], its low viral load makes it difficult to determine the etiological significance.

A Taiwanese study reported a significant association between HPV-16/18 and lung adenocarcinomas (ACs) among nonsmoking female patients [5]. We also reported a higher prevalence of high-risk HPV in ACs (30%, 9/30) than that of SQCs (7%, 2/27) [6]. Furthermore, high-risk HPV genome was more frequently observed in lung ACs with response to gefitinib (75%, 6/8) than that of those without response to the treatment (0%, 0/12) [6].

Clinical responsiveness to gefitinib is associated with somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene [7], [8], which are most frequently observed in lung ACs of non-smoking women in far-East Asian countries [9]. It is worth noting that these clinicopathological features, non-smoking female lung ACs, are similar to that observed in the Taiwanese study [5].

In the present study, we investigated the association between EGFR mutations and the presence of HPV DNA in Japanese lung cancer. Furthermore, viral load and physical status of high-risk HPV-16 were examined.

Section snippets

Clinical specimens

The present study examined a total of 42 paraffin-embedded tissue samples of lung cancer cases, including 26 ACs, 12 SQCs and 4 other histological types, diagnosed at Kagoshima University Hospital during the period from December 2007 to December 2008. Institutional Review Boards of Kagoshima University Hospital, Japan, approved the present study.

HPV detection, typing and physical status

The HPV genome was detected by PCR with broad-spectrum SPF10-biotinylated primers [10]. HPV typing was performed using the INNO-LiPA HPV Genotyping CE

Results

Among 42 lung tumors, 13 cases (31%) had mutations in either exon 19 or 21 of the EGFR gene (Table 1). Exon 19 deletion and exon 21 L858R were detected in 7 (54%) and 6 (46%) out of 13 mutations, respectively. These mutations were mutually exclusive. The frequency of the mutations was significantly higher in smaller tumors (Table 1, P = 0.043).

HPV DNA was detected in 7/42 (17%) lung tumors (Table 1). HPV-16 was the most frequently detected type (n = 5). High-risk HPV-58 was detected in the

Discussion

The present study showed a significant association between high-risk HPV detection and EGFR mutations in Japanese lung cancer cases (P = 0.021). Similar results were described in a Taiwanese study [14]. On the other hand, EGFR mutations were quite rare in cervical cancer [15], and the EGFR mutations were not related to HPV presence in SQCs of the tongue and tonsil [16]. These findings suggest that the association between EGFR mutations and HPV presence is restricted to lung cancer.

HPV-16

Conflict of interest

None declared.

Acknowledgements

This study was supported by Grants-in-Aid for Scientific Research on Priority Areas (17015037) of the Ministry of Education, Culture, Sports, Science and Technology, Japan. We thank Ms. Yoshie Minakami for excellent technical work and Joint Research Laboratory, Kagoshima University Graduate School of Medical and Dental Sciences, for the use of their facilities.

References (28)

  • J.G. Paez et al.

    EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

    Science

    (2004)
  • T.J. Lynch et al.

    Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

    N Engl J Med

    (2004)
  • T. Mitsudomi et al.

    Biological and clinical implications of EGFR mutations in lung cancer

    Int J Clin Oncol

    (2006)
  • P. Peitsaro et al.

    Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique

    J Clin Microbiol

    (2002)
  • Cited by (28)

    • Association of Merkel cell polyomavirus infection with EGFR mutation status in Chinese non-small cell lung cancer patients

      2014, Lung Cancer
      Citation Excerpt :

      It is interesting that EGFR mutations were reported to be associated with high-risk type human papillomaviruses (HPVs) infection in Japanese patients with lung cancer [26]. Furthermore, the EGFR/PI3K/AKT cascade may play a pivotal role in carcinogenesis of HPV-related lung cancer [26,27]. Virus genome mutagenesis happens frequently, which is necessary for defending from host immune system or exogenous anti-virus agents and fulfilling carcinogenesis role [28].

    • Human papilloma virus in non-small cell lung cancer in never smokers: A systematic review of the literature

      2014, Lung Cancer
      Citation Excerpt :

      Because smoking status was not fully reported in all studies, we contacted the authors by e-mail to supplement this information. Eleven studies from East Asia [10–20] (N = 1110), four from Europe [7,21–23] (N = 569) and one from America [24] (N = 30) provided information on smoking status (Table 1). These data showed the distribution of HPV infection with NSCLC in never smokers (31.4%, 95% CI 27.2–35.9%, N = 452).

    • Natural selection and functional diversification of the epidermal growth factor receptorEGFR family in vertebrates

      2013, Genomics
      Citation Excerpt :

      Tyrosine kinases of the EGFR family are frequently mutated in human cancers. Mutations in the tyrosine kinase domain of EGFR (encoded by exons 18–24) have mostly been found in lung cancers [47–51]. There were seven positive selections detected in the ErbB family: three positive selection sites (30V, 47H, 51L) were located in exon 2, two sites (637P, 638T) were located in exon 18, one site (639N) was located in exon 19 and one site (1060I) was located in exon 29; however, our research still has some discrepancies with the present experimental study.

    • High-risk human papillomavirus-positive lung cancer: Molecular evidence for a pattern of pulmonary metastasis

      2013, Journal of Thoracic Oncology
      Citation Excerpt :

      The present study in a Dutch population suggests no association between hrHPV and EGFR mutations. The low viral loads found in the Asian studies37,38 makes it difficult to determine the etiological significance of their findings. Our findings of pulmonary metastatic disease are in line with those of case studies reporting on the occurrence of hrHPV–positive pulmonary metastases of cervical cancer, head-and–neck squamous cell carcinoma, and penile cancer.39–41

    View all citing articles on Scopus
    View full text